255 related articles for article (PubMed ID: 35631363)
1. A Comprehensive Review of the Cardiovascular Protective Properties of Silibinin/Silymarin: A New Kid on the Block.
Kadoglou NPE; Panayiotou C; Vardas M; Balaskas N; Kostomitsopoulos NG; Tsaroucha AK; Valsami G
Pharmaceuticals (Basel); 2022 Apr; 15(5):. PubMed ID: 35631363
[TBL] [Abstract][Full Text] [Related]
2. Bio-Actives from Natural Products with Potential Cardioprotective Properties: Isolation, Identification, and Pharmacological Actions of Apigenin, Quercetin, and Silibinin.
Tomou EM; Papakyriakopoulou P; Skaltsa H; Valsami G; Kadoglou NPE
Molecules; 2023 Mar; 28(5):. PubMed ID: 36903630
[TBL] [Abstract][Full Text] [Related]
3. A systematic review of the protective effects of silymarin/silibinin against doxorubicin-induced cardiotoxicity.
Singh M; Kadhim MM; Turki Jalil A; Oudah SK; Aminov Z; Alsaikhan F; Jawhar ZH; Ramírez-Coronel AA; Farhood B
Cancer Cell Int; 2023 May; 23(1):88. PubMed ID: 37165384
[TBL] [Abstract][Full Text] [Related]
4. Potential Pharmaceutical Applications of Quercetin in Cardiovascular Diseases.
Papakyriakopoulou P; Velidakis N; Khattab E; Valsami G; Korakianitis I; Kadoglou NP
Pharmaceuticals (Basel); 2022 Aug; 15(8):. PubMed ID: 36015169
[TBL] [Abstract][Full Text] [Related]
5. The Radioprotective Potentials of Silymarin/Silibinin Against Radiotherapy- Induced Toxicities: A Systematic Review of Clinical and Experimental Studies.
Latacela GA; Ramaiah P; Patra I; Jalil AT; Gupta R; Madaminov FA; Shaker Shafik S; Al-Gazally ME; Ansari MJ; Kandeel M; Mustafa YF; Farhood B
Curr Med Chem; 2023; 30(33):3775-3797. PubMed ID: 36424777
[TBL] [Abstract][Full Text] [Related]
6. Role of silibinin in the management of diabetes mellitus and its complications.
Chu C; Li D; Zhang S; Ikejima T; Jia Y; Wang D; Xu F
Arch Pharm Res; 2018 Aug; 41(8):785-796. PubMed ID: 29978427
[TBL] [Abstract][Full Text] [Related]
7. Antiproliferative and apoptotic effects of silibinin in rat prostate cancer cells.
Tyagi A; Bhatia N; Condon MS; Bosland MC; Agarwal C; Agarwal R
Prostate; 2002 Nov; 53(3):211-7. PubMed ID: 12386921
[TBL] [Abstract][Full Text] [Related]
8. The cardiovascular-protective properties of saffron and its potential pharmaceutical applications: A critical appraisal of the literature.
Kadoglou NPE; Christodoulou E; Kostomitsopoulos N; Valsami G
Phytother Res; 2021 Dec; 35(12):6735-6753. PubMed ID: 34448254
[TBL] [Abstract][Full Text] [Related]
9. The Radiosensitizing Potentials of Silymarin/Silibinin in Cancer: A Systematic Review.
Gupta J; Turki Jalil A; Al-Hawraa Riyad Muedii Z; Aminov Z; Alsaikhan F; Ramírez-Coronel A; Ramaiah P; Farhood B
Curr Med Chem; 2023 Oct; ():. PubMed ID: 37921180
[TBL] [Abstract][Full Text] [Related]
10. Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention.
Zhao J; Agarwal R
Carcinogenesis; 1999 Nov; 20(11):2101-8. PubMed ID: 10545412
[TBL] [Abstract][Full Text] [Related]
11. Silymarin versus Silibinin: Differential Antioxidant and Neuroprotective Effects against H2O2-induced Oxidative Stress in PC12 Cells.
Jiang HH; Yan FS; Shen L; Ji HF
Nat Prod Commun; 2016 May; 11(5):633-6. PubMed ID: 27319137
[TBL] [Abstract][Full Text] [Related]
12. Silymarin inhibits growth and causes regression of established skin tumors in SENCAR mice via modulation of mitogen-activated protein kinases and induction of apoptosis.
Singh RP; Tyagi AK; Zhao J; Agarwal R
Carcinogenesis; 2002 Mar; 23(3):499-510. PubMed ID: 11895866
[TBL] [Abstract][Full Text] [Related]
13. Biochemical bases of the pharmacological action of the flavonoid silymarin and of its structural isomer silibinin.
Valenzuela A; Garrido A
Biol Res; 1994; 27(2):105-12. PubMed ID: 8640239
[TBL] [Abstract][Full Text] [Related]
14. Regulation of gut microbiota in Alzheimer's disease mice by silibinin and silymarin and their pharmacological implications.
Shen L; Liu L; Li XY; Ji HF
Appl Microbiol Biotechnol; 2019 Sep; 103(17):7141-7149. PubMed ID: 31236617
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of human carcinoma cell growth and DNA synthesis by silibinin, an active constituent of milk thistle: comparison with silymarin.
Bhatia N; Zhao J; Wolf DM; Agarwal R
Cancer Lett; 1999 Dec; 147(1-2):77-84. PubMed ID: 10660092
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer prevention by silibinin.
Singh RP; Agarwal R
Curr Cancer Drug Targets; 2004 Feb; 4(1):1-11. PubMed ID: 14965263
[TBL] [Abstract][Full Text] [Related]
17. Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels.
Singh RP; Dhanalakshmi S; Tyagi AK; Chan DC; Agarwal C; Agarwal R
Cancer Res; 2002 Jun; 62(11):3063-9. PubMed ID: 12036915
[TBL] [Abstract][Full Text] [Related]
18. Antioxidant effects and mechanism of silymarin in oxidative stress induced cardiovascular diseases.
Taleb A; Ahmad KA; Ihsan AU; Qu J; Lin N; Hezam K; Koju N; Hui L; Qilong D
Biomed Pharmacother; 2018 Jun; 102():689-698. PubMed ID: 29604588
[TBL] [Abstract][Full Text] [Related]
19. Silymarin and silibinin cause G1 and G2-M cell cycle arrest via distinct circuitries in human prostate cancer PC3 cells: a comparison of flavanone silibinin with flavanolignan mixture silymarin.
Deep G; Singh RP; Agarwal C; Kroll DJ; Agarwal R
Oncogene; 2006 Feb; 25(7):1053-69. PubMed ID: 16205633
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic interaction between oltipraz and silymarin in rats.
Kang MK; Bae SK; Kim JW; Lee MG
J Pharm Pharm Sci; 2009; 12(1):1-16. PubMed ID: 19470289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
